Related references
Note: Only part of the references are listed.Practical management of tyrosine kinase inhibitor-associated side effects in GIST
Heikki Joensuu et al.
CANCER TREATMENT REVIEWS (2011)
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
Paul W. Manley et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
Ann W. Gramza et al.
CLINICAL CANCER RESEARCH (2009)
A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
M. Montemurro et al.
EUROPEAN JOURNAL OF CANCER (2009)
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALL
Arinobu Tojo et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Molecular characterization of pediatric gastrointestinal stromal tumors
Narasimhan P. Agaram et al.
CLINICAL CANCER RESEARCH (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
Philipp le Coutre et al.
BLOOD (2008)
Sorafenib inhibits the imatinib-resistant KITT6701 gatekeeper mutation in gastrointestinal stromal tumor
Tianhua Guo et al.
CLINICAL CANCER RESEARCH (2007)
Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group
A. Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group
Jean-Yves Blay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
Narasimhan P. Agaram et al.
CLINICAL CANCER RESEARCH (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
Deborah L. White et al.
BLOOD (2006)
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines
Hans Prenen et al.
PHARMACOLOGY (2006)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
JR Zalcberg et al.
EUROPEAN JOURNAL OF CANCER (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
LL Chen et al.
CANCER RESEARCH (2004)
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas et al.
BLOOD (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
